|
🦁
|
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment.
9 auth.
A. Fabi,
R. Bhargava,
S. Fatigoni,
M. Guglielmo,
M. Horneber,
F. Roila,
...
J. Weis,
K. Jordan,
C. Ripamonti
|
8 |
2020 |
8
🦁
|
|
🐜
|
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
21 auth.
X. Pivot,
A. Manikhas,
B. Żurawski,
E. Chmielowska,
B. Karaszewska,
R. Allerton,
S. Chan,
A. Fabi,
P. Bidoli,
S. Gori,
...
E. Ciruelos,
M. Dank,
L. Hornyák,
S. Margolin,
A. Nusch,
R. Parikh,
F. Nagi,
M. Desilvio,
S. Santillana,
R. Swaby,
V. Semiglazov
|
7 |
2015 |
7
🐜
|
|
🐜
|
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
20 auth.
P. Pedrazzoli,
A. Farris,
S. D. Del Prete,
F. Del Gaizo,
D. Ferrari,
C. Bianchessi,
G. Colucci,
A. Desogus,
T. Gamucci,
A. Pappalardo,
...
G. Fornarini,
P. Pozzi,
A. Fabi,
R. Labianca,
F. di Costanzo,
S. Secondino,
E. Crucitta,
F. Apolloni,
A. Del Santo,
S. Siena
|
7 |
2008 |
7
🐜
|
|
🐜
|
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
12 auth.
G. Metro,
J. Foglietta,
M. Russillo,
L. Stocchi,
A. Vidiri,
D. Giannarelli,
...
L. Crinò,
P. Papaldo,
M. Mottolese,
F. Cognetti,
A. Fabi,
S. Gori
|
7 |
2011 |
7
🐜
|
|
🐬
|
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
S. Di Cosimo,
G. Ferretti,
P. Papaldo,
P. Carlini,
A. Fabi,
F. Cognetti
|
7 |
2003 |
7
🐬
|
|
🐜
|
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
8 auth.
M. Aapro,
A. Fabi,
F. Nolè,
M. Médici,
G. Steger,
C. Bachmann,
...
S. Roncoroni,
F. Roila
|
7 |
2010 |
7
🐜
|
|
🐬
|
RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
M. Infante,
A. Fabi,
F. Cognetti,
S. Gorini,
M. Caprio,
A. Fabbri
|
7 |
2019 |
7
🐬
|
|
🐜
|
Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients
14 auth.
G. Ferretti,
A. Fabi,
P. Carlini,
P. Papaldo,
P. Cordiali Fei,
S. Di Cosimo,
N. Salesi,
D. Giannarelli,
A. Alimonti,
B. Di Cocco,
...
G. D'Agosto,
V. Bordignon,
E. Trento,
F. Cognetti
|
7 |
2005 |
7
🐜
|
|
🐜
|
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
18 auth.
G. Minuti,
F. Cappuzzo,
R. Duchnowska,
J. Jassem,
A. Fabi,
Terence J. O'Brien,
A. D. Mendoza,
L. Landi,
W. Biernat,
B. Czartoryska-Arłukowicz,
...
T. Jankowski,
D. Zuziak,
J. Żok,
B. Szostakiewicz,
M. Foszczyńska‐Kłoda,
A. Tempińska-Szałach,
E. Rossi,
M. Varella-Garcia
|
6 |
2012 |
6
🐜
|
|
🐜
|
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
13 auth.
F. Novelli,
M. Milella,
E. Melucci,
A. di Benedetto,
I. Sperduti,
R. Perrone-Donnorso,
L. Perracchio,
I. Venturo,
C. Nisticó,
A. Fabi,
...
S. Buglioni,
P. Natali,
M. Mottolese
|
6 |
2008 |
6
🐜
|
